ALDH1B1 Knockout A-549 Polyclonal Cells are a population of A-549 lung adenocarcinoma epithelial cells engineered via CRISPR/Cas9-mediated gene disruption to create a loss-of-function model for the mitochondrial aldehyde dehydrogenase ALDH1B1. As polyclonal knockout cells, the population contains heterogeneous disruptive mutations that collectively ablate ALDH1B1 enzymatic activity, enabling functional studies without clonal isolation.
The A-549 cell line, derived from a 58-year-old Caucasian male with lung adenocarcinoma, is a well-characterized model of type II alveolar epithelial cells widely employed in lung cancer biology, drug resistance, and respiratory research. These adherent cells retain alveolar type II features, including surfactant synthesis and responsiveness to oncogenic and metabolic stimuli. In this knockout context, A-549 provides a malignant background for dissecting ALDH1B1??s contributions to lung adenocarcinoma physiology.
At the molecular level, ALDH1B1 catalyzes the NAD+-dependent oxidation of retinaldehyde to all-trans retinoic acid (ATRA), which activates nuclear receptors RAR?? and RXR to regulate gene transcription. ALDH1B1 expression is controlled by transcription factors such as SP1, C/EBP??, and retinoic acid receptors. In A-549 cells, knockout eliminates ATRA synthesis, attenuating RAR/RXR-mediated transcriptional programs and impairing HOX gene expression. This disruption reduces stem cell markers OCT4 and SOX2 via diminished ??-catenin/TCF/LEF signaling downstream of Wnt pathway activation. Loss of ALDH1B1 also compromises detoxification of reactive aldehydes, heightening oxidative stress and potentially altering ABC transporter efflux. Interaction with NAD+ and possible crosstalk with ALDH1A1 underscore its metabolic significance.
In lung adenocarcinoma, ALDH1B1 is implicated in cancer stem cell maintenance, tumor initiation, and chemoresistance, making its knockout in A-549 cells a powerful tool. The A-549 line harbors KRAS mutations typical of lung adenocarcinoma, offering a context to examine ALDH1B1??s enzymatic and non-enzymatic roles. Knocking out ALDH1B1 enables evaluation of how retinoic acid depletion affects tumor cell plasticity, epithelial-mesenchymal transition, and stem-like cell self-renewal. As a polyclonal population, this model reflects tumor heterogeneity, facilitating studies of clonal variation in pathway dependence and adaptive responses.
Researchers can apply these cells to interrogate retinoic acid-dependent transcription via RNA-seq and RT-qPCR, quantify ALDH activity with Aldefluor, perform sphere-formation assays, and assess drug sensitivity to cisplatin and doxorubicin. Additional applications include oxidative stress assays, migration/invasion studies, and western blotting for markers such as OCT4, SOX2, and cleaved caspase-3. These tools enable comprehensive dissection of ALDH1B1 function in lung adenocarcinoma biology. For further information, contact Ascent Research.
